The quick reply Lex (and Ice) is that only a big pharma can afford the bills to take this through Phase 3 trials.
Ann: HSV-2 Phase IIa Results Investor Webinar, page-160
-
- There are more pages in this discussion • 137 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.00 |
Change
0.150(1.01%) |
Mkt cap ! $317.0M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.15 | $14.30 | $210.2K | 14.26K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $14.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.00 | 5153 | 3 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |